睿知中国医院研究地图
候选清单

正在招募肺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 19 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 19

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心蚌埠医学院第一附属医院First Affiliated Hospital of Bengbu Medical University蚌埠医院页面
  2. 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
  3. 研究中心中山大学附属第一医院First Affiliated Hospital of Sun Yat-sen University广州医院页面
  4. 研究中心中国科学技术大学附属第一医院(安徽省立医院)First Affiliated Hospital of USTC合肥医院页面
  5. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  6. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  7. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  8. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  9. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  10. 研究中心南通市肿瘤医院Nantong Tumor Hospital南通医院页面
  11. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  12. 研究中心中南大学湘雅二医院Second Xiangya Hospital长沙医院页面
  13. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  14. 研究中心同济大学附属东方医院Shanghai East Hospital, Tongji University上海医院页面
  15. 研究中心上海市肺科医院Shanghai Pulmonary Hospital上海医院页面
  16. 研究中心汕头大学医学院附属医院Shantou University Medical College hospitals汕头医院页面
  17. 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
  18. 研究中心四川大学华西医院West China Hospital成都医院页面
  19. 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06793215,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed diagnosis of advanced or metastatic non squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy

    入选标准第 2 条

  3. History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival [OS] rate >90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer

    排除标准第 14 条

  4. Any anti-cancer systemic therapy, including hormonal therapy, within 21 days prior to randomization, or is expected to require any other form of antineoplastic therapy while in the study

    排除标准第 7 条

    Prior treatment with KRAS G12C inhibitors or pan-KRAS/RAS inhibitors

    排除标准第 9 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

    入选标准第 1 条

  6. Measurable disease, as defined by RECIST v1.1

    入选标准第 3 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06793215,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  2. Histologically or cytologically confirmed diagnosis of advanced or metastatic non squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy
  3. Measurable disease, as defined by RECIST v1.1
  4. No prior systemic treatment for advanced or metastatic NSCLC
  5. Documentation of the presence of a KRAS G12C mutation
  6. Documentation of known PD-L1 expression status in tumor tissue
  7. Availability of a representative tumor specimen
  8. Adequate end-organ function
  9. Eligible to receive a platinum-based chemotherapy regimen

排除标准:Exclusion Criteria:

  1. Known concomitant second oncogenic driver with available targeted treatment
  2. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  3. Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for >=2 weeks prior to randomization
  4. History of leptomeningeal disease
  5. Uncontrolled tumor-related pain
  6. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once a month or more frequently)
  7. Any anti-cancer systemic therapy, including hormonal therapy, within 21 days prior to randomization, or is expected to require any other form of antineoplastic therapy while in the study
  8. Radiation therapy including palliative RT to bone metastases within 2 weeks prior to randomization and RT to the lung >30Gy within 6 months prior to randomization
  9. Prior treatment with KRAS G12C inhibitors or pan-KRAS/RAS inhibitors
  10. Treatment with systemic immunosuppressive or immunostimulatory medications, including CD137 agonists and immune checkpoint inhibitors
  11. Current treatment with medications that are well known to prolong the QT interval
  12. Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to randomization
  13. Prior allogeneic stem cell or solid organ transplantation
  14. History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival [OS] rate >90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer
  15. Individuals with chronic diarrhea, short bowel syndrome or significant upper gastrointestinal surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or any active bowel inflammation (including diverticulitis), malabsorption syndrome, conditions that would interfere with enteral absorption
  16. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest computed tomography scan
  17. Significant cardiovascular disease within 3 months prior to screening

引自 ClinicalTrials.gov, NCT06793215, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06793215,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06793215